Ometab

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ometab

Property Description
Active ingredient Omeprazole
Form Tablet, Delayed-release capsule
Pharmacological class Proton pump inhibitor (PPI)
Common purpose Acid reduction
Origin Synthetic compound

Ometab is the specific trade designation for a medicinal product whose active component is omeprazole, a potent member of the proton pump inhibitor (PPI) pharmacological class. This classification immediately defines the medication as an antisecretory compound, utilized to manage conditions linked to excessive gastric acid production. The compound is chemically categorized as a substituted benzimidazole, and it is manufactured as a synthetic compound. The classification of omeprazole as a benchmark PPI is clinically recognized for providing sustained acid suppression.

The core identity of Ometab places it within the group of antiulcer drugs, distinct from older acid-reducing agents. Omeprazole functions by achieving the irreversible inhibition of the proton pump, which is the final biological mechanism responsible for the secretion of acid in the stomach. This mechanism ensures a predictable and significant reduction in acid levels.


Composition, Form, and General Purpose

The active component, omeprazole, is a single active ingredient product designed to be administered via the oral route. Ometab is commonly supplied as a tablet, though the active ingredient is broadly available in forms such as a delayed-release capsule or gastro-resistant capsule. Omeprazole is included on the Model List of Essential Medicines.

The formulation's gastro-resistant property is a critical design feature, pharmacologically supported to ensure the omeprazole passes safely through the highly acidic environment of the stomach without being degraded. This allows the drug to reach the small intestine for absorption and subsequent systemic availability. Ometab's general purpose is centered on its acid-reducing action, providing the foundational benefit of consistently lowering the acid content in the stomach to mitigate factors that can cause irritation or damage to the sensitive upper digestive tract lining.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Ometab?

The safety profile of Ometab (omeprazole) is officially defined by government regulatory documents, which classify potential adverse reactions based on their frequency and the system-organ class involved. This information is presented in a neutral, descriptive manner, strictly adhering to regulatory classifications.

Official Adverse Reactions by Frequency

The most frequently reported adverse reactions are classified as Common (may affect up to 1 in 10 people) and typically involve the Gastrointestinal System and Nervous System. These include abdominal pain, constipation, diarrhea, flatulence, nausea/vomiting, and headache. Reactions categorized as Uncommon (up to 1 in 100 people) include dizziness, somnolence, insomnia, malaise, and increased liver enzymes.

Reactions classified as Rare or Very Rare are also documented, encompassing severe hypersensitivity reactions (e.g., anaphylactic shock), certain blood disorders (leukopenia, agranulocytosis), and mental disturbances (e.g., confusion, depression).

Serious Adverse Reactions and Safety Patterns

The regulatory profile lists several Serious Adverse Reactions that are rare but clinically significant. These include severe cutaneous reactions, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), hepatic failure, and acute interstitial nephritis.

Safety notes tied to duration of exposure are also documented. Long-term use (typically ge 1 year) is officially associated with the potential for hypomagnesemia (low magnesium levels) and an increased risk of bone fracture (hip, wrist, or spine). The label also notes that patients with pre-existing severe liver disease have a documented very rare risk of encephalopathy.

This structured safety information, derived exclusively from regulatory sources, forms the basis for understanding the medicine’s risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with omeprazole (Ometab) requires immediate medical attention and is managed through symptomatic and supportive care, as officially documented by regulatory authorities.

Documented Overdose Manifestations

In documented cases involving high doses of omeprazole (up to 900 mg), the reported symptoms were typically transient and short-lived. The officially recognized clinical manifestations include a cluster of effects such as confusion, drowsiness, headache, and blurred vision. Other reported signs may include tachycardia (fast heart rate), nausea, diaphoresis (increased sweating), flushing, and dry mouth.

Regulatory-Mandated Emergency Actions

It is officially stated that no serious clinical outcome has been reported in connection with omeprazole overdosage alone. However, an overdose scenario requires that one seek immediate medical advice. Management is strictly defined as symptomatic and supportive treatment.

Furthermore, regulatory information confirms that no specific antidote is known for omeprazole. The active substance is extensively protein bound, meaning it is not readily dialyzable, which defines the procedural approach to overdose management.

Therapeutic Uses of Ometab

Quick Facts

  • Primary Use: Supports the management of symptoms associated with Gastroesophageal Reflux Disease (GERD).
  • Secondary Uses: Indicated for managing duodenal and gastric ulcers, and for treatment of conditions causing excessive stomach acid production.

What Ometab Treats: Main Uses and Benefits

Ometab is a medication prescribed to support the management of several conditions related to acid production in the stomach. The primary use is the management of symptoms associated with Gastroesophageal Reflux Disease (GERD), which may include heartburn and other discomforts. This medication is available as an option to assist in the healing of erosive esophagitis, a condition that involves tissue damage in the esophagus due to acid-mediated GERD.

Additionally, Ometab is indicated for the short-term management of active duodenal ulcer and active benign gastric ulcer. It may also be used as a component of combination therapy to reduce the risk of duodenal ulcer recurrence associated with Helicobacter pylori (H. pylori) infection.

The medication also serves as an intervention for pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, where the stomach produces an excessive amount of acid. This intervention is intended to help maintain appropriate acid levels and support patient comfort.

Eligibility and Restrictions for Use

Who can and cannot use Ometab? — Official Regulatory Information

Eligibility Scope

Population Group Eligibility Status
Populations for whom use is allowed Adults, Older Adults, Pediatric patients ge 1 year, Infants ge 1 month
Populations for whom use is not recommended Breastfeeding women (unless use is essential)
Populations for whom use is contraindicated Hypersensitivity, Concomitant use with Nelfinavir or Rilpivirine-containing products, Patients with rare hereditary excipient intolerance

Age-Related Eligibility Rules

  • Use is established for all adults and older adults, with no required dose adjustment based on age.
  • Pediatric use is established for infants ge 1 month for certain conditions; safety and effectiveness have not been established for children younger than 1 month of age.

Condition-Specific Eligibility Rules

  • Hepatic Impairment: Dose reduction should be considered for patients with severe liver impairment.
  • Renal Impairment: Dose adjustment is not needed for patients with impaired kidney function.
  • The presence of gastric malignancy must be excluded before initiating treatment for gastric ulceration.

Pregnancy and Lactation Eligibility Status

  • Pregnancy: Use is generally limited to instances where the potential benefit justifies the potential risk to the fetus.
  • Lactation: Omeprazole is secreted in breast milk, and use is generally advised only when considered essential by the prescribing authority.

Eligibility Classifications (High-Level)

  • Eligibility Severity Classification: Contraindicated (for allergy, Nelfinavir/Rilpivirine, hereditary intolerance); Not Established (for infants <1 month); Restriction/Caution (for Hepatic Impairment, Pregnancy/Lactation).
  • Regulatory Basis: Statements are based on official government labeling (FDA Prescribing Information and EMA Summary of Product Characteristics).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ometab (Omeprazole) has officially documented interaction patterns structured primarily around two pharmacokinetic mechanisms: its effect as an acid reducer and its activity as an inhibitor of the CYP2C19 enzyme. This results in altered systemic exposure for several co-administered medicinal products, which mandates specific restrictions.


Official Regulatory Interaction Categories

Classification Interacting Substances/Examples
Contraindicated Combinations Nelfinavir, Rilpivirine (HIV antivirals)
Exposure-Increasing Interactions Diazepam, Cilostazol, Digoxin, Tacrolimus
Exposure-Decreasing Interactions Ketoconazole, Itraconazole, Dasatinib, Iron Salts

Restrictions and Conditions

Co-administration with Nelfinavir and Rilpivirine is contraindicated because the increase in gastric pH significantly reduces the absorption and plasma concentrations of these drugs. Omeprazole's inhibition of CYP2C19 results in elevated exposure for substrates like Diazepam and Cilostazol. Conversely, it reduces the pharmacological effect of the prodrug Clopidogrel, leading to a recommendation that co-administration be avoided.

Use with strong enzyme inducers like St. John's Wort and Rifampin is avoided because they may reduce the systemic concentration of Omeprazole. Additionally, regulatory documents require a cessation of treatment at least 14 days before conducting diagnostic testing for Chromogranin A ( CgA) to prevent interference with test results.

Mechanism of Action

Irreversible Blockade of the Proton Pump

This section covers the drug's core molecular mechanism: the precise targeting and permanent deactivation of the gastric acid enzyme. Omeprazole acts as a specific, acid-activated prodrug that concentrates in the parietal cells and forms an irreversible covalent bond with the H^+,K^+-ATPase (Proton Pump) . This action results in the blockade of the final common pathway of acid secretion, regardless of the neural or hormonal signals attempting to stimulate it, leading directly to an antisecretory state.


⏳ Time-Dependent Onset and Sustained Effect

This domain explains the kinetics of the mechanism, specifically its duration and time to achieve maximum effect. Due to its irreversible binding, the drug's duration of action is constrained not by its elimination from the body, but by the physiological rate of synthesis of new proton pumps (enzyme turnover), contributing to the sustained elevation of intragastric pH for up to 24 hours. The drug preferentially targets actively secreting pumps, meaning a maximal physiological effect is only achieved gradually over several days as more pumps cycle into an active state and become permanently inhibited.

Dosage and Administration Information

Official Instructions for Use

Ometab (omeprazole) is administered orally and is typically taken once daily. The specific instructions for administration are designed to ensure the delayed-release formulation is effective.

Administration Component Regulatory Instruction
Route & Frequency Taken once daily (unless otherwise prescribed).
Timing Administer before a meal, preferably in the morning.
Procedural Steps Swallow the tablet whole with a glass of water. Do not chew or crush the delayed-release tablet.
Missed Dose Take the missed dose as soon as it is remembered. If it is almost time for the next scheduled dose, skip the missed dose and take the next dose at the regular time. Do not take two doses at once.
OTC Course Limit For non-prescription (OTC) use in adults (18 years and older), the course of treatment is 14 days. This 14-day course should not be repeated more often than every 4 months unless directed by a healthcare professional.

These official guidelines establish the protocol for consuming the medicine, ensuring that the delayed-release mechanism remains intact by prohibiting crushing or chewing. They mandate once-daily administration before a meal to align with optimal drug action and specify strict limits for the duration and repetition of the non-prescription treatment course. Dosage for pediatric patients is determined by weight and must be prescribed by a physician.

Recent Clinical Evidence

Ometab: Recent Clinical Evidence

The foundational research for Ometab (Omeprazole) includes numerous Randomized Controlled Trials (RCTs) and meta-analyses reported in scientific literature. These studies were used to investigate how the compound affects symptoms and physical outcomes related to acid backing up into the esophagus, a condition known as Gastroesophageal Reflux Disease (GERD).


Evidence for Managing Acid-Related Symptoms and Esophageal Damage

Research explored how symptoms change over time in conditions characterized by fluctuating manifestations. Short-term RCTs monitored patient-reported outcomes describing perceived discomfort in both adults and pediatric patients with diagnosed GERD symptoms, comparing the compound to placebo or other classes of acid reducers. Studies reported how symptoms evolved, with findings describing patterns in the proportion of patients reporting a change in symptoms.

For Erosive Esophagitis (EE), trials focused on objective measures. Researchers used endoscopy to track the endoscopic healing rate of tissue damage. Studies reported measurements of how quickly and completely the damage closed up. Evidence quality varies regarding the relationship between achieving physical healing and patient-reported outcomes related to symptoms.


Evidence for Healing and Preventing Ulcers

Short-term RCTs evaluated the compound in adults with confirmed active ulcers (duodenal and gastric). Studies monitored endoscopic healing and time needed for patients to report a change in discomfort levels. For H. pylori eradication, research examined the compound as part of a combination treatment with antibiotics. Studies reported the percentage of patients achieving confirmed bacterial elimination and tracked long-term measurements of duodenal ulcer recurrence.


Research Gaps and Limitations

Long-term studies extending significantly beyond one year are limited in the primary controlled literature. Data regarding the compound's activity against acute, sudden episodes of heartburn is less characterized. Furthermore, evidence quality varies for rare conditions like Zollinger-Ellison syndrome, where data relies on small-scale observational studies, meaning that research provides context but not individual predictions for patients with complex medical backgrounds.

Key Studies & References

  1. OMEPRAZOLE Delayed-Release Capsules Prescribing Information - DailyMed (NIH/FDA Monograph)

Frequently Asked Questions (FAQ)

Common questions about Ometab (FAQ)


Q: Is Ometab a type of antibiotic or a pain reliever?

Ometab is classified as a Proton Pump Inhibitor (PPI). This type of medication works by targeting a specific enzyme in the stomach wall to decrease the amount of acid the stomach produces, which distinguishes it from antibiotics or pain relievers.


Q: Is Ometab considered a long-term treatment option?

According to official product information, non-prescription (OTC) use is limited to a 14-day course that should not be repeated more often than every four months unless directed by a healthcare professional. For prescription use involving certain chronic conditions, the medication is indicated for longer periods under the guidance of a physician.


Q: Can Ometab affect my ability to drive or operate machinery?

Official side effect information notes that this medication may cause dizziness or drowsiness. Because these effects have been reported, patients should be aware of the possibility that alertness may be affected.


Q: Is it normal to feel tired when starting Ometab?

Some patients in clinical reports have experienced side effects such as tiredness, weakness, or drowsiness. These are noted in the adverse reaction information as effects that can occur during use.


Q: Why is Ometab prescribed for more than one condition?

The medication is effective for several different conditions because of its specific mechanism of action. It works by blocking the final common pathway of acid secretion, meaning it reduces acid production regardless of the type of signal attempting to stimulate it. This single action helps treat a variety of acid-related problems, such as ulcers and reflux disease.


Q: Do I need to change my diet while taking Ometab?

Official instructions specify that Ometab should be administered before a meal to align with its known administration guidelines. Specific changes or restrictions to your overall diet are not mandated in the regulatory documents.


Q: Is Ometab known to cause weight gain or weight loss?

The official adverse reaction data includes reports of rapid weight gain and, rarely, unexplained weight loss in the post-marketing experience section.


Q: What are the most frequent or common side effects listed for Ometab?

The most common adverse reactions reported in clinical trials (incidence ge 2%) include headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence.


Q: Can women who are planning to become pregnant use Ometab?

Official information addresses use during an established pregnancy but does not specifically detail use for women who are actively planning to become pregnant. Official documents do not provide specific guidance on use during the planning stage.


Q: Can Ometab cause dry mouth or changes in taste?

Yes, official adverse reaction information lists dry mouth, as well as disturbances in taste (such as taste perversion or taste disturbances), as effects that have been reported by patients.


Q: Are there any long-term side effects associated with Ometab use?

Regulatory documents contain warnings regarding potential risks associated with prolonged use (typically one year or longer). These include an increased risk of bone fracture, low magnesium levels (hypomagnesemia), and, less commonly, vitamin B12 deficiency.


Q: Can Ometab be taken if I have a history of depression or anxiety?

Official adverse reaction reports list psychiatric effects such as depression and anxiety, which have been reported in the post-marketing setting.


Q: Why do some people feel dizzy when they first take Ometab?

Dizziness is listed in regulatory documents as a common side effect (occurring in 1% to 10% of patients) reported during use.


Q: What happens if Ometab is stopped suddenly?

Regulatory documents indicate that prescription use is not recommended to be stopped without consulting a healthcare professional, as stopping may lead to a quick return of symptoms.


Q: Is there a generic version of Ometab available?

Yes, the generic name for Ometab is omeprazole, and it is available under this generic name as well as various brand names.


Q: Is Ometab addictive or habit-forming?

Since regulatory documents do not classify this medication as a controlled substance, it is not listed as being addictive or habit-forming.


Q: Does Ometab require a special storage temperature?

Yes, the official labeling includes specific storage instructions. The medication should be stored at controlled room temperature, typically 20-25 C ( 68-77 F), and protected from moisture.


Q: Are there official restrictions on Ometab based on age or weight?

Official labeling provides indications for use in adults and in pediatric patients 2 years of age and older. Dosing for younger pediatric patients is typically determined based on weight and must be prescribed by a healthcare professional.


Q: Is Ometab metabolized by the liver?

Yes, according to the official clinical pharmacology information, the medication is extensively metabolized by the CYP enzyme system. This process is primarily carried out by the liver.


Q: Does taking Ometab impact my sleep schedule?

Insomnia (trouble sleeping) has been reported as a common side effect in some patients. Other sleep disturbances have also been noted in official post-marketing reports.


Q: Does Ometab interact with caffeine or alcohol?

Official drug interaction studies found no direct interaction between this medication and alcohol. There are no official regulatory warnings or specific interaction studies listed concerning caffeine.


Q: How quickly does Ometab start to have an effect?

The medication is not intended for immediate relief of symptoms. Non-prescription labeling indicates that it may take 1 to 4 days of continued use for the full acid-reducing benefit to be felt, though symptom relief may begin sooner for some patients.


Q: What is the average duration of Ometab's effect?

Due to its mechanism, which involves irreversibly binding to the proton pump, the drug's acid-decreasing effect can be sustained for up to 24 hours after a single dose.


Q: What is the typical timeframe for seeing the full benefits of Ometab?

Official labeling states it may take 1 to 4 days of continued use for the full benefit of the medication to be felt. This is because the drug gradually targets the actively producing acid pumps over time.


Q: Are there specific vitamins or supplements that should not be taken with Ometab?

Official information highlights that long-term use (usually one year or more) may lead to a decrease in the absorption and levels of certain vitamins and minerals, specifically Vitamin B12 and magnesium. This information is based on official safety warnings related to nutritional deficiency.


Q: Can Ometab be used by older adults (e.g., those over 65)?

While use is generally permitted, official warnings note that older adults may be at a higher risk for osteoporosis-related bone fractures, particularly with long-term or high-dose use of the medication.


Q: Is Ometab ever used in children or adolescents?

Yes, the prescription medication is indicated for the treatment of certain acid-related conditions in pediatric patients 2 years of age and older.


Q: Can Ometab make sun sensitivity worse?

Increased sensitivity of the skin to sunlight (photosensitivity) and severe sunburn have been reported as side effects in the post-marketing setting.


Q: Is it possible to be allergic to an inactive ingredient in Ometab?

Yes, the drug is officially contraindicated (should not be used) for those with a known hypersensitivity or allergy to any component of the formulation. This includes both the active drug and the inactive ingredients.


Q: What kind of monitoring (e.g., blood tests) might be needed while taking Ometab?

Official product information notes that, for patients on the medication for one year or longer, monitoring for signs of low magnesium levels and vitamin B12 deficiency may be considered.

How should Ometab be stored and disposed of?

Storage and Disposal of Omeprazole Delayed-Release Capsules

Required Storage Conditions

Omeprazole delayed-release capsules must be stored at controlled room temperature, maintaining a range of 20°C to 25°C (68°F to 77°F). The medication must be kept away from high heat and requires explicit protection from moisture.

To preserve the product’s integrity, it is a regulatory requirement to keep the capsules in the original container and ensure the container is tightly closed at all times.

Child Safety and Disposal

For safety, the product must be stored strictly out of reach of children. When disposing of expired or unused medicine, State and local government guidelines must be followed. Regulators advise utilizing a drug take-back program if available. If a take-back option is not accessible, the product should be mixed with an unappealing substance and placed in a sealed bag for disposal in the household trash; the medicine should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ometab found in:

A-Z Index: